Published :
Tables : 45
Figures : 43
Category : Healthcare
No. of Pages : 224
Report Code : HC-1142
Hemato Oncology Testing Market Introduction Hemato Oncology Testing Market is estimated to value over USD 5.2 billion by 2029 end and register a CAGR of over 14.6% during the forecast period 2020 to 2029. The type of product and service, the global hemato oncology market is bifurcated into services segment and assay kits segment. Based on the type of cancer, the market is categorised as leukaemia, acute myeloid leukaemia, acute lymphocytic leukaemia, lymphoma, non-hodgkin lymphoma, hodgkin lymphoma and others. As leukaemia patients require continuous monitoring and considering the ever-increasing number of leukaemia cases worldwide, this segment is anticipated to dominate the market during the forecast period. Technology-wise, the market is bifurcated into PCR, NGS, IHC, Cytogenetics and others. PCR technology segment is anticipated to showcase a significant market growth in 2019 owing to the ease of use and availability of assay kits. Global Hemato Testing Oncology Market Regional Insight The market is geographically segmented into North America, Europe, Asia Pacific and rest of the world. North America is expected to dominate the global market during the forecast period owing to a growing awareness of advanced treatment theories, a strong presence of key market players in the region and availability of reimbursement for hemato oncology testing products. Major Key Players in Hemato Oncology Testing Market : • F. Hoffmann-La Roche Ltd. • Abbott Laboratories • Thermo Fisher Scientific Inc. • Illumine Inc. • Molecular MD • Invivoscribe Inc. • Qiagen N.V. • Bio-Rad Laboratories, Inc. • Archerdx, Inc. • Arup Laboratories Inc. • Asuragen, Inc. • Adaptive Biotechnologies. • Cepheid • Entrogen, Inc. Hemato Testing Oncology Market Segmentation: By Region • North America • Europe • Asia Pacific • Rest of the World By Product & Service Type • Services • Assay Kits By Cancer Type • Leukemia o Acute Myeloid Leukemia (AML) o Acute Lymphocytic Leukemia (ALL) o Chronic Lymphocytic Leukemia o Chronic Myeloid Leukemia • Lymphoma o Non-Hodgkin Lymphoma o Hodgkin Lymphoma • Myeloproliferative Neoplasms o Polycythemia vera (PV) o Essential thrombocythemia (ET) o Myelofibrosis (MF) • Other Cancers By Technology • PCR • NGS • IHC • Cytogenetics • Others By End User • Clinical laboratories • Hospitals • Academic & Research Institutes • Other End Users (CROs, Pharmaceutical & Biotechnology Companies) Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Hemato Oncology Testing Market By Product & Service Type, By Cancer Type, By Technology, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and rest of the world • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization services offered are free of charge with purchase of any license of the report. You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Hemato Oncology Testing Market is estimated to value over USD 5.2 billion by 2029 end and register a CAGR of over 14.6% during the forecast period 2020 to 2029.
The type of product and service, the global hemato oncology market is bifurcated into services segment and assay kits segment. Based on the type of cancer, the market is categorised as leukaemia, acute myeloid leukaemia, acute lymphocytic leukaemia, lymphoma, non-hodgkin lymphoma, hodgkin lymphoma and others. As leukaemia patients require continuous monitoring and considering the ever-increasing number of leukaemia cases worldwide, this segment is anticipated to dominate the market during the forecast period.
Technology-wise, the market is bifurcated into PCR, NGS, IHC, Cytogenetics and others. PCR technology segment is anticipated to showcase a significant market growth in 2019 owing to the ease of use and availability of assay kits.
The market is geographically segmented into North America, Europe, Asia Pacific and rest of the world. North America is expected to dominate the global market during the forecast period owing to a growing awareness of advanced treatment theories, a strong presence of key market players in the region and availability of reimbursement for hemato oncology testing products.
Major Key Players in Hemato Oncology Testing Market : • F. Hoffmann-La Roche Ltd. • Abbott Laboratories • Thermo Fisher Scientific Inc. • Illumine Inc. • Molecular MD • Invivoscribe Inc. • Qiagen N.V. • Bio-Rad Laboratories, Inc. • Archerdx, Inc. • Arup Laboratories Inc. • Asuragen, Inc. • Adaptive Biotechnologies. • Cepheid • Entrogen, Inc.
By Region • North America • Europe • Asia Pacific • Rest of the World
By Product & Service Type • Services • Assay Kits
By Cancer Type • Leukemia o Acute Myeloid Leukemia (AML) o Acute Lymphocytic Leukemia (ALL) o Chronic Lymphocytic Leukemia o Chronic Myeloid Leukemia • Lymphoma o Non-Hodgkin Lymphoma o Hodgkin Lymphoma • Myeloproliferative Neoplasms o Polycythemia vera (PV) o Essential thrombocythemia (ET) o Myelofibrosis (MF) • Other Cancers
By Technology • PCR • NGS • IHC • Cytogenetics • Others
By End User • Clinical laboratories • Hospitals • Academic & Research Institutes • Other End Users (CROs, Pharmaceutical & Biotechnology Companies)
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Hemato Oncology Testing Market By Product & Service Type, By Cancer Type, By Technology, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and rest of the world • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Cancer Typeology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Hemato Oncology Testing Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Hemato Oncology Testing Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Hemato Oncology Testing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Hemato Oncology Testing Market, By Product & Service Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Services 7.2. Assay Kits 8. Global Hemato Oncology Testing Market, By Cancer Type Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Leukemia 8.1.1. Acute Myeloid Leukemia (AML) 8.1.2. Acute Lymphocytic Leukemia (ALL) 8.1.3. Chronic Lymphocytic Leukemia 8.1.4. Chronic Myeloid Leukemia 8.2. Lymphoma 8.2.1. Non-Hodgkin Lymphoma 8.2.2. Hodgkin Lymphoma 8.3. Myeloproliferative Neoplasms 8.3.1. Polycythemia vera (PV) 8.3.2. Essential thrombocythemia (ET) 8.3.3. Myelofibrosis (MF) 8.4. Other Cancers 9. Global Hemato Oncology Testing Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. PCR 9.2. NGS 9.3. IHC 9.4. Cytogenetics 9.5. Others 10. Global Hemato Oncology Testing Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Clinical laboratories 10.2. Hospitals 10.3. Academic & Research Institutes 10.4. Diagnostic Laboratories 10.5. Other End Users (CROs, Pharmaceutical & Biotechnology Companies) 11. North America Hemato Oncology Testing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2020-2027 12. Latin America Hemato Oncology Testing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2020-2027 13. Europe Hemato Oncology Testing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2020-2027 14. Asia Pacific Hemato Oncology Testing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million) Forecast for MEA 2020-2027 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product & Service Types Offered and Financial Layouts) 17.1. F. Hoffmann-La Roche Ltd. 17.1.1. Company Overview 17.1.2. Mode of operation Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Abbott Laboratories 17.2.1. Company Overview 17.2.2. Mode of operation Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Thermo Fisher Scientific Inc. 17.3.1. Company Overview 17.3.2. Mode of operation Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Illumine Inc. 17.4.1. Company Overview 17.4.2. Mode of operation Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Molecular MD 17.5.1. Company Overview 17.5.2. Mode of operation Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Invivoscribe Inc. 17.6.1. Company Overview 17.6.2. Mode of operation Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Qiagen N.V. 17.7.1. Company Overview 17.7.2. Product & Service Type Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Bio-Rad Laboratories, Inc. 17.8.1. Company Overview 17.8.2. Product & Service Type Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Archerdx, Inc. 17.9.1. Company Overview 17.9.2. Product & Service Type Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Arup Laboratories Inc.. 17.10.1. Company Overview 17.10.2. Product & Service Type Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Asuragen, Inc. 17.11.1. Company Overview 17.11.2. Technology Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Adaptive Biotechnologies. 17.12.1. Company Overview 17.12.2. Technology Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Cepheid 17.13.1. Company Overview 17.13.2. Technology Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.Entrogen, Inc. 17.14.1. Company Overview 17.14.2. Technology Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders
2. Research Cancer Typeology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study
3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights
4. Global Hemato Oncology Testing Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Hemato Oncology Testing Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Hemato Oncology Testing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Global Hemato Oncology Testing Market, By Product & Service Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Services 7.2. Assay Kits
8. Global Hemato Oncology Testing Market, By Cancer Type Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Leukemia 8.1.1. Acute Myeloid Leukemia (AML) 8.1.2. Acute Lymphocytic Leukemia (ALL) 8.1.3. Chronic Lymphocytic Leukemia 8.1.4. Chronic Myeloid Leukemia 8.2. Lymphoma 8.2.1. Non-Hodgkin Lymphoma 8.2.2. Hodgkin Lymphoma 8.3. Myeloproliferative Neoplasms 8.3.1. Polycythemia vera (PV) 8.3.2. Essential thrombocythemia (ET) 8.3.3. Myelofibrosis (MF) 8.4. Other Cancers
9. Global Hemato Oncology Testing Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. PCR 9.2. NGS 9.3. IHC 9.4. Cytogenetics 9.5. Others
10. Global Hemato Oncology Testing Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Clinical laboratories 10.2. Hospitals 10.3. Academic & Research Institutes 10.4. Diagnostic Laboratories 10.5. Other End Users (CROs, Pharmaceutical & Biotechnology Companies)
11. North America Hemato Oncology Testing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2020-2027
12. Latin America Hemato Oncology Testing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2020-2027
13. Europe Hemato Oncology Testing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2020-2027
14. Asia Pacific Hemato Oncology Testing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million) Forecast for MEA 2020-2027
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product & Service Types Offered and Financial Layouts) 17.1. F. Hoffmann-La Roche Ltd. 17.1.1. Company Overview 17.1.2. Mode of operation Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Abbott Laboratories 17.2.1. Company Overview 17.2.2. Mode of operation Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Thermo Fisher Scientific Inc. 17.3.1. Company Overview 17.3.2. Mode of operation Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Illumine Inc. 17.4.1. Company Overview 17.4.2. Mode of operation Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Molecular MD 17.5.1. Company Overview 17.5.2. Mode of operation Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Invivoscribe Inc. 17.6.1. Company Overview 17.6.2. Mode of operation Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Qiagen N.V. 17.7.1. Company Overview 17.7.2. Product & Service Type Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Bio-Rad Laboratories, Inc. 17.8.1. Company Overview 17.8.2. Product & Service Type Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Archerdx, Inc. 17.9.1. Company Overview 17.9.2. Product & Service Type Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Arup Laboratories Inc.. 17.10.1. Company Overview 17.10.2. Product & Service Type Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Asuragen, Inc. 17.11.1. Company Overview 17.11.2. Technology Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Adaptive Biotechnologies. 17.12.1. Company Overview 17.12.2. Technology Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Cepheid 17.13.1. Company Overview 17.13.2. Technology Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.Entrogen, Inc. 17.14.1. Company Overview 17.14.2. Technology Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview
18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics